To review the latest research on the treatment of metastatic colorectal cancer (mCRC) using physical ablation (PA) combined with immune checkpoint inhibitors (ICIs).
Key Findings:
ICIs have shown good therapeutic effects in some mCRC patients, but overall response rates remain low.
PA can enhance anti-tumor immunity and synergize with ICIs to improve treatment outcomes.
The combination of PA and ICIs can reshape the tumor immune microenvironment.
Interpretation:
The combination of PA and ICIs may provide a new treatment strategy to improve clinical prognosis in mCRC.
Limitations:
The article does not provide specific clinical trial data or outcomes.
Challenges in the combined treatment approach are not fully explored.
Conclusion:
The review aims to provide insights into a potential new treatment strategy for mCRC by combining PA with ICIs.
